Central Nervous System News and Research

RSS

Researchers recommend traumatic brain injury reclassification for additional funding

Traumatic brain injury, currently considered a singular event by the insurance industry and many health care providers, is instead the beginning of an ongoing process that impacts multiple organ systems and may cause or accelerate other diseases and disorders that can reduce life expectancy, according to research from the University of Texas Medical Branch at Galveston.

27 Aug 2010

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

Mental disorders, such as depression, anxiety disorders, addiction and schizophrenia are the core challenge of most health care systems around the world. In the EU alone, each year 27% of the total adult population - this corresponds to 83 Million citizens - suffer from mental disorders. Depression alone affects almost 20 million ranking in the EU as the most disabling disorder of all diseases.

26 Aug 2010

Afferent Pharmaceuticals' P2X3 receptor antagonist reduces bladder hyperactivity

Afferent Pharmaceuticals, a clinical-stage biopharmaceutical company developing first-in-class, small molecule compounds that target P2X3 receptors, today announced preclinical in vivo results demonstrating that an investigational P2X3 receptor antagonist reduced experimentally induced bladder hyperactivity.

26 Aug 2010

Aileron Therapeutics, Roche partner to develop, commercialise Stapled Peptide Therapeutics

Aileron Therapeutics and Roche announced today that they have entered into a collaboration to discover, develop and commercialise a new class of drugs called Stapled Peptide Therapeutics. As part of this agreement, Roche will work with Aileron to develop drug candidates against up to five undisclosed targets selected from Roche's key therapeutic areas, which include oncology, virology, inflammation, metabolism and CNS.

24 Aug 2010

Alpha-synuclein gene silencing effective for treating neurodegenerative disorders: Research

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at The Parkinson's Institute and the Mayo Clinic have published new research findings in the journal Public Library of Science (PLoS). The new data show effective silencing of the alpha-synuclein gene with an RNAi therapeutic administered directly to the substantia nigra in the CNS of non-human primates.

24 Aug 2010

Human neural stem cells restore motor function in mice with chronic spinal cord injury

StemCells, Inc. announced today the publication of new preclinical data demonstrating that the Company's proprietary human neural stem cells restore lost motor function in mice with chronic spinal cord injury. This is the first published study to show that human neural stem cells can restore mobility even when administered at time points beyond the acute phase of trauma, suggesting the prospect of treating a much broader population of injured patients than previously demonstrated.

20 Aug 2010

ISCO to formalize eye care based stem cell therapeutic programs into Cytovis business unit

International Stem Cell Corporation, today announced that its stem cell therapeutic programs focused on protective, transparent corneas (CytoCor™) in the front of the eye and the light-sensitive retinal tissue (CytoRet™) in the back of the eye will be formalized into a new business unit, Cytovis™.

20 Aug 2010

UCI study is first to show reversal of long-term hind-limb paralysis

A UC Irvine study is the first to demonstrate that human neural stem cells can restore mobility in cases of chronic spinal cord injury, suggesting the prospect of treating a much broader population of patients.

20 Aug 2010

Cognition Therapeutics receives grant to develop small-molecule drug candidate for Alzheimer's disease

The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant of $228,668 to Cognition Therapeutics (CogRx) to develop small molecule drugs that block the action of the toxic "oligomers" thought responsible for Alzheimer's disease (AD).

19 Aug 2010

Rush University Medical Center tests new drug therapy for West Nile fever

Neurological and infectious disease experts at Rush University Medical Center are testing a new drug therapy for the treatment of individuals with West Nile fever or suspected central nervous system infection due to the West Nile virus. Rush is the only site in the Midwest enrolling patients into the $50 million dollar, NIH-funded, Phase II clinical trial called PARADIGM.

18 Aug 2010

Evaluation of medical reasons behind end to pregnancy due to abnormalities of fetus important

When a pregnancy ends tragically due to fatal abnormalities of the fetus, it is important to understand the medical reasons behind the event. This evaluation can help predict the risk of reoccurrence in future pregnancies. In the case of fetal akinesia deformation sequence (FADS), the fetus may have been affected by a disrupting injury or unavoidable maldevelopment.

18 Aug 2010

Chronix Biomedical expands biomarker development capabilities with installation of DNA mass sequencer

Chronix Biomedical today reported that it has significantly expanded and accelerated its biomarker development capabilities with the installation of Germany's first state-of-the-art high-throughput DNA mass sequencer at the University of Göttingen, Chronix's long-time collaborator. Chronix is developing disease-specific biomarkers based on DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells.

17 Aug 2010

Air quality along US Gulf Coast improves after stoppage of oil leak

The oil spill along the United States Gulf Coast poses health risks to volunteers, fishermen, clean-up workers and members of coastal communities, according to a new commentary by UCSF researchers who spent time in the region and are among the first to look into health problems caused by the oil spill. The good news, the authors say, is that one of the risk factors, coastal air quality, is improving now that the oil leak has been stopped.

17 Aug 2010

Ill effects of methamphetamine

On the street it's known as meth, speed, ice, chalk, crank, fire, glass or crystal. Methamphetamine is a highly addictive drug that wreaks havoc on the entire body, including the user's oral health. Approximately 10 million Americans have tried methamphetamine, while more than 1.4 million are habitual users.

17 Aug 2010

KemPharm receives patent for LAT prodrug technology for Attention Deficit – Hyperactivity Disorder treatment

KemPharm, Inc. announced today that it has received a Notice of Issuance from the United States Patent and Trademark Office (USPTO) for its patent application entitled "Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same", U.S. Patent No. 7,772,222. This patent protects broad aspects of the Company's core Ligand Activated Therapy (LAT) prodrug technology platform and its application to the treatment of Attention Deficit – Hyperactivity Disorder.

16 Aug 2010

CeNeRx BioPharma raises $13 million through Series C financing to support TriRima Phase II trial

CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced completion of a $13 million Series C financing. Existing investors Perseus Soros Biopharmaceutical Fund, L Capital Partners and Pappas Ventures all participated in the financing. CeNeRx plans to use the proceeds to conduct a Phase II trial of its improved formulation of its novel antidepressant TriRima™.

13 Aug 2010

EUROPEAN BIOTECHNICA AWARD finalists announced

The names of the finalists in this year's EUROPEAN BIOTECHNICA AWARD have been announced. The companies Addex Pharmaceuticals (Switzerland), Apeiron Biologics (Austria) and Galapagos Genomics (Belgium) have made it through to the final round.

13 Aug 2010

Neurologix second-quarter net loss increases to $4.5 million

Neurologix, Inc., a biotechnology company developing innovative gene therapies for the brain and central nervous system, today reported its financial results for the three and six months ended June 30, 2010.

13 Aug 2010

Study examines impact of microvascular decompression surgery for type 2 diabetes

A team of Allegheny General Hospital (AGH) physicians led by neurosurgical pioneer Peter Jannetta, MD, has made an important new discovery linking the central nervous system to the onset and progression of type 2 diabetes mellitus.Reporting today in the journal Surgical Neurology International, Dr. Jannetta and his colleagues present evidence from a prospective clinical trial that vascular compression of a section of the brain called the medulla oblongata is a factor in some patients with type 2 diabetes and that microvascular decompression surgery (MVD) may be an effective treatment for the condition.

13 Aug 2010

NextWave Pharmaceuticals, Tris Pharma sign agreement to enhance CNS product portfolio

NextWave Pharmaceuticals and Tris Pharma, both privately held companies, announced a new collaboration agreement to enhance NextWave's CNS product portfolio utilizing Tris Pharma's unique drug delivery technology for liquid and solid formulations. Tris has reacquired the rights to non CNS products including all the OTC products previously licensed to NextWave Pharmaceuticals.

12 Aug 2010

Central Nervous System News and Research

Researchers recommend traumatic brain injury reclassification for additional funding

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

Afferent Pharmaceuticals' P2X3 receptor antagonist reduces bladder hyperactivity

Aileron Therapeutics, Roche partner to develop, commercialise Stapled Peptide Therapeutics

Alpha-synuclein gene silencing effective for treating neurodegenerative disorders: Research

Human neural stem cells restore motor function in mice with chronic spinal cord injury

ISCO to formalize eye care based stem cell therapeutic programs into Cytovis business unit

UCI study is first to show reversal of long-term hind-limb paralysis

Cognition Therapeutics receives grant to develop small-molecule drug candidate for Alzheimer's disease

Rush University Medical Center tests new drug therapy for West Nile fever

Evaluation of medical reasons behind end to pregnancy due to abnormalities of fetus important

Chronix Biomedical expands biomarker development capabilities with installation of DNA mass sequencer

Air quality along US Gulf Coast improves after stoppage of oil leak

Ill effects of methamphetamine

KemPharm receives patent for LAT prodrug technology for Attention Deficit – Hyperactivity Disorder treatment

CeNeRx BioPharma raises $13 million through Series C financing to support TriRima Phase II trial

EUROPEAN BIOTECHNICA AWARD finalists announced

Neurologix second-quarter net loss increases to $4.5 million

Study examines impact of microvascular decompression surgery for type 2 diabetes

NextWave Pharmaceuticals, Tris Pharma sign agreement to enhance CNS product portfolio

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News